Specifically, ERα36 has been reported to up-regulate EGFR expression and down-regulate of ERα66 expression in human breast cancer cells, suggesting that this could represent an underlying mechanism for the generation of acquired tamoxifen-resistance in breast cancer patients [80]. This evidence concerns the gene EGFR and breast carcinoma.